Infiltration tendency of internal mammary lymph nodes involvement in patients with breast cancer: anatomical characteristics and implications for target delineation

Yujie Wang 1, Weixiang Qi 1, Haoping Xu 1, Miao Zhang 2, Yimin Han 1, Jiayi Chen 1 and Cheng Xu 1*

Abstract

Background: Despite increasing clinical data suggest that internal mammary node (IMN) irradiation would improve local-regional control and overall survival in breast cancer, its role remains controversial due to increased risk of cardiac and pulmonary toxicity. The current study aims to determine the high risk areas of IMN metastases by collecting and analyzing the axial imaging of IMN involvement, in order to optimize IMN delineation for breast cancer.

Methods: Breast cancer patients with IMN involvement were retrospectively identified from single-center database. All available imaging modalities including thoracic CT, breast MRI, ultrasound and PET/CT were used to diagnose IMN metastases. Anatomical characteristics from axial imaging, including distribution of involved ribs and distance from the internal mammary vessels (IMV), were collected for each metastatic IMN. What’s more, the natural infiltration tendency of IMNs from IMV was calculated in this study.

Results: In total, 83 metastatic IMNs from 70 breast cancer patients (initial diagnosed: 34 and recurrence: 36) were located from axial CT image in this study. The second intercostal space was the most likely involved in patients with single ($n = 35, 53.0\%$) and multiple intercostal space ($n = 31, 47.0\%$) involvement. The percentage of including IMN with a 5 mm, 6 mm and 7 mm medial/lateral distance to the IMV were $75.9\%$ (63/83), $89.2.6\%$ (74/83) and $92.3\%$ (77/83) respectively. While in maximal dorsal/ventral distance, nearly 95% of the nodes were encompassed into 6 mm depth to the IMV. Over 65% of IMN adenopathy (32/49, 65.3%) were found to have a growth direction close to the sternum. By retrospective reviewing diagnostic reports, MRI demonstrated a high diagnostic performance in diagnosis of IMN disease (90.3%, 28/31), while CT had a higher misdiagnosis rate (22/63, 34.9%). The diagnostic efficiency of IMN could be improved if different methods were combined.

Conclusions: For patients with indications of prophylactic IMN irradiation, a 7 mm medial and 6 mm dorsal distance to the IMV on axial CT image would be optimal to cover the clinical volume of IMN; and it would be reasonable to extend clinical tumor volume (CTV) coverage towards sternum for patients with evident IMN disease. Multi-imaging modalities are recommended to improve the diagnostic specificity and sensitivity of IMN metastases.

Keywords: IMN, IMV, Anatomical features, Infiltration tendency, CTV delineation

© The Author(s). 2019. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
As a primary lymphatic draining site in breast, increasing attention has been paid to the internal mammary lymph node chain along with the axillary lymph nodal basin. Evidence from radical (Halsted) mastectomy in the 1950s has validated that nearly one third of breast cancer patients would experience IMN involvement on surgical biopsies [1, 2]. Modern Lymphatic mapping techniques such as isosulfan blue dye and technetium-99 labeled sulfur colloid or the combination of both, has confirmed that approximately 25% (ranges: 13 to 37%) of breast cancer patients have primary IMN drainage. In addition, the position of the tumor in the media and the status of positive axillary lymph node are independent risk factors for IMN involvement [3–6]. It was also established that patients with IMN metastases have a worse prognosis than patients who do not, independent of their axillary status [7–11]. Therefore, how to appropriately manage IMN chain becomes a hot issue in breast cancer treatment.

Radiotherapy, after the surgical intervention, has been a widely accepted standard of care in the management of breast cancer for appropriate indications, as shown by numerous randomized trials and meta-analyses which confirm that RT could significantly decrease the risk of LRR and improve overall survival. EBCTCG meta-analyses, along with EORTC 22922–10,925, MA.20, and DBCG-IMN clinical trials have shown a significant benefit of local-regional control and survival in positive axillary lymph nodes (ALNs) or high-risk ALN negative breast cancer patients who receiving regional node irradiation (RNI) [12–16]. Based on these practice-changing randomized controlled studies, internal mammary lymph node irradiation was delivered as part of post-mastectomy or post-lumpectomy radiation therapy in addition to systemic therapy in some subgroup of breast cancer with high-risk features.

Despite these positive evidence, to include IMN as part of RNI or not has not reached a consensus. One reason could be its anatomical position immediately adjacent to heart and lungs. Thus IMN irradiation would increase the dose and volume of normal tissue radiated, especially in left-sided patients might offset the therapeutic effect of IMN irradiation [17–19]. Additionally, anthracycline-based chemotherapy and concurrent administration of trastuzumab with adjuvant radiation therapy for HER2-positive patients may also exacerbate heart toxicity [19–22].

Given the anatomical location of the IMNs and adjuvant system regimens, inclusion of IMN in the RNI would inevitably increase the complexity of the treatment planning [17]. And current recommendations for CTV of IMN remain controversial. For example, the PROCAB, DBCG, and ESTRO groups suggest a uniform 5-mm expansion on the IM vessels, while RTOG guideline encompasses the IMV only [23–26]. As a result, it would be helpful to optimally cover the clinical volume of IMN and minimize normal tissue volume exposure in the era of intensity-modulate radiotherapy (IMRT).

What is worse, within the image characteristics of regional nodes involvement in breast cancer, data on IMN involvement is relatively scarce than others. Despite the lower frequency of IMN metastasis compared to ALN, lack of sensitivity in radiological early detection and no universal consensus for abnormal IMN on imageological diagnosis also explain to the insufficient report [27–30].

The aim of the current study is to locate and map the involved IMN in order to improve the existing recommendation of IMN contouring guideline. Also, by search on radiological system using possible confounding description, to reveal the existence of under-diagnosis of IMN metastasis in real world.

Methods
Patients with diagnostic breast cancer and complete imaging records for any possible internal mammary nodes involvement were retrospectively identified from breast cancer database at a single institution. Strings or terms for searching, including “internal mammary node”, “IM node”, parasternal mass/lump or chest-wall mass/lump, were used to identify imaging slices with abnormal IMN(s) as documented by a breast radiologist. Image methods included in the search contain ultrasound, thoracic CT, breast MRI, and PET/CT. Each imaging slice with possible abnormal IMN(s) was reviewed by a senior radiologist and a radiation oncologist independently on the basis of suspicious radiographic appearance including shape, size, contrast enhancement, MRI signal and fluorodeoxy-glucose avidity, and a final determination was reached on the consensus. The axial CT image with the most evident mass in the internal mammary node region would be selected for subsequent calculation and measurement if multiple records was retrieved with the same patient. IMN greater than 5 mm in short axis was defined as metastasis in this study.

For each patient, anatomical characteristics from axial CT image including the number and size of the involved IM lymph node(s), intercostal space location(s) were documented, and distance from the center of node to IMV were measured for each metastatic node. To analyze the nature extending direction of IMNs, we anchored the ipsilateral IMV as center and measured the distance from the farthest point of the lesion to the vessel. On the axial CT image, the position of the IM vessel was marked firstly, and then the maximum distance of the mass from different directions in each quadrant was measured and spotted to calculate the probability of falling within each quadrant. Figure 1 displays the schematic diagram of the measurement.
Chi-square test was employed to compare the differences between these spots located in the four quadrants. \( P < 0.05 \) was considered to be of statistical significance. Statistical analysis was performed with SPSS software.

## Results

### Patient characteristics

In total, 83 metastatic IMNs in 70 breast cancer patients (four patients with bilateral breast cancer) were identified with the aforementioned diagnostic criteria. The IMNs were located from axial CT image in this study and seven cases were measured from PET/CT series. Thirty-four patients were identified IMN metastases at initial diagnosis and 36 recurrent with or without distance metastasis, among whom four patients were lack of initial diagnostic imaging information. Seventeen patients also had axillary regional nodes involvement concurrently, 14 patients had primary distant metastasis at initial diagnosis. Among the patients with relapse or metastases, only nine patients had IMNs recurrence alone, while the rest patients had concurrent local-regional recurrence and/or metastases. Four patients had pathologically confirmed IMN disease via extend radical mastectomy. Biopsy of the IMN was not routine as most patients had simultaneously confirmed metastases in the axillary or the supraclavicular lymph nodes that were sampled by fine-needle aspiration (FNA). The management of IMNs recurrence was performed at the physician’s discretion, 10 patients did undergo FNA of the suspected IMN under the guidance of ultrasound or CT, and cytology confirmed metastatic carcinoma were diagnosed in all of these patients. The general characteristics of the study group were shown in Table 1.

### Anatomic characteristics of IMN metastases

**IMNs in relation to intercostal spaces**

The number of metastatic nodes located in the 1st, 2nd, 3rd and 4th intercostal space was 28 (42.4%), 58 (87.9%), 20 (30.3%) and 4 (6.1%) respectively. The second intercostal space was the most likely invaded among patients not only with single \((n = 35, 53.0\%)\) but also with multiple intercostal spaces \((n = 31, 47.0\%)\) involvement. Only four
IMNs were distributed in the 4th intercostal space and one was continued from the subclavian vein. Table 2 shows the intercostal locations of the study group.

### IMNs in relation to IMVs

The maximal radial distance from center of metastatic nodes to the IMV in each patient were measured and documented. The percentage of including IMN with a 4 mm, 5 mm, 6 mm and 7 mm medial/lateral distance to the IMV were 54.2% (45/83), 75.9% (63/83), 89.2% (74/83) and 92.3% (77/83) respectively. While in maximal dorsal/ventral distance, all extension of the IMN nodes were in dorsal direction, the percentage of including IMN with a 4 mm, 5 mm, 6 mm and 7 mm depth to the IMV were 88% (73/83), 91.6% (76/83), 96.4% (80/83) and 98.8% (82/83) respectively, one case had enlarged mass invading the fourth rib, for which the measurement was difficult.

### Natural infiltration expansion of the IMNs progression

Overall, 49 cases with visible IMN adenopathy larger than 1 cm in diameter was evaluated to analyze the tendency of natural extension. All cases of IMNs were mapped manually using CT imaging of a female patient who had left-sided IMN relapse. Her CT scan of the chest with intravenous contrast acquired with both arms abducted overhead and uploaded onto the Eclipse planning system. After labeling the farthest point of IMN

### Table 1 General characteristics of study group

| Characteristics | Initial diagnosis with IMN involved (n = 34) | Recurrence with IMN involved (n = 36) | All patients (n = 70)* |
|-----------------|--------------------------------------------|--------------------------------------|-----------------------|
| **ER status, n(%)** |                                            |                                      |                       |
| Positive        | 20 (58.8)                                  | 25 (69.4)                            | 45 (64.3)             |
| Negative        | 12 (35.3)                                  | 10 (27.8)                            | 22 (31.4)             |
| Unknown         | 2 (5.9)                                    | 1 (2.8)                              | 3 (4.3)               |
| **PR status, n(%)** |                                            |                                      |                       |
| Positive        | 13 (38.2)                                  | 19 (52.8)                            | 32 (45.7)             |
| Negative        | 18 (52.9)                                  | 15 (41.7)                            | 33 (47.1)             |
| Unknown         | 3 (8.8)                                    | 2 (5.6)                              | 5 (7.1)               |
| **HER2 status, n(%)** |                                            |                                      |                       |
| Positive        | 12 (35.3)                                  | 11 (30.6)                            | 23 (32.9)             |
| Negative        | 20 (58.8)                                  | 22 (61.1)                            | 42 (60.0)             |
| Unknown         | 2 (5.9)                                    | 3 (8.3)                              | 5 (7.1)               |
| **T stage, n(%)** |                                            |                                      |                       |
| Tis             | 1 (2.9)                                    | 0 (0)                                | 1 (1.4)               |
| T1              | 4 (11.8)                                   | 10 (27.8)                            | 14 (20.0)             |
| T2              | 13 (38.2)                                  | 17 (47.2)                            | 30 (42.9)             |
| T3              | 4 (11.8)                                   | 2 (5.6)                              | 6 (8.6)               |
| T4              | 8 (23.5)                                   | 1 (2.8)                              | 9 (12.9)              |
| Tx              | 4 (11.8)                                   | 6 (16.7)                             | 10 (14.3)             |
| **N stage, n(%)** |                                            |                                      |                       |
| N0              | 0 (0)                                      | 19 (52.8)                            | 19 (27.1)             |
| N1              | 0 (0)                                      | 6 (16.7)                             | 6 (8.6)               |
| N2              | 1 (2.9)                                    | 3 (8.3)                              | 4 (5.7)               |
| N3              | 33 (97.1)                                  | 6 (16.7)                             | 39 (55.7)             |
| Nx              | 0 (0)                                      | 2 (5.6)                              | 2 (2.9)               |
| **M status, n(%)** |                                            |                                      |                       |
| M0              | 20 (58.8)                                  | 15 (41.7)                            | 35 (50.0)             |
| M1              | 14 (41.2)                                  | 21 (58.3)                            | 35 (50.0)             |

*Including four patients with bilateral breast cancer
Four patients had missing information
metastatic lesions on axial CT imaging, 32 patients (65.3%, 32/49) were found to have a growth direction towards sternum, and 23 of them (71.9%, 23/32) tend to spread above the sternum (Fig. 2). Invasion of the sternum was observed in 12 cases. Unfortunately, no significant difference was obtained with $P$ value over 0.05 ($P = 0.38$).

### Diagnostic rate of different imaging method

The diagnostic rates of enlarged IMN detected on US, CT, MR, and PET–CT are approximately 36.0% (18/50), 34.9% (22/63), 90.3% (28/31) and 13.0% (3/23), respectively. Most frequent description displayed as “parasternal mass/lump” and “chest-wall mass/lump” for CT diagnostic documents. The diagnostic efficiency of IMN can be increased to 67.4% if we combined different imaging methods.

### Discussion

Involvement of internal mammary nodes is considered to be an ominous prognostic factor, both in the setting of initial diagnosis and the recurrence. A large population-based study concluded that IMN recurrence could perform as a forerunner of metastatic disease after a long-term follow-up of 6000 breast cancer patients [11]. A most recent study mapping the anatomic pattern of isolated nodal recurrences demonstrated a relatively higher occurrence of IMN recurrence (32.5%) following axillary

---

**Table 2** Involved ribs location and local-regional relapse of study group

| Involved region   | Initial diagnosis | Recurrent | Summary |
|-------------------|-------------------|-----------|---------|
|                   | $n = 34$          | $n = 32^*$| $n = 66$ (%)|
| IMN (pts/No)      | M0 14             | M0 14     | 66      |
| 1st intercostal   | 5 10              | 6 7       | 28 (42.4)|
| 2nd intercostal   | 17 13             | 11 17     | 58 (87.9)|
| 3rd intercostal   | 3 4               | 4 9       | 20 (30.3)|
| 4th intercostal   | 0 2               | 0 2       | 4 (6.1) |
| Single intercostal| 15 4              | 7 9       | 35 (53.0)|
| ≥1 intercostal    | 5 10              | 7 9       | 31 (47.0)|
| Local recurrence  | – –               | 9 8       | 17 (53.1)**|
| ALN I             | 19 13             | 0 3       | 35 (53.0)|
| ALN II            | 13 10             | 1 7       | 31 (47.0)|
| ALN III           | 9 8               | 1 6       | 24 (36.4)|
| SCN               | 5 5               | 4 9       | 23 (34.8)|

*Four cases lack of diagnostic imaging data, not included in the statistics

** Proportion of IMN in combination with local recurrence in relapsed population

Abbreviations: IMN, Internal mammary lymph node; ALN Axillary lymph node; SCN, supraclavicular node

---

Fig. 2 Natural expansion of the IMNs progression. More dots are located in the area near sternum
nodes (42%) with least recurrence of supraclavicular area (25.5%) compared with the rare recurrence rate from other studies [10]. It also presented as an portent for significantly inferior overall survival when compared with an axillary recurrence with no IMN involvement. For breast cancer patients with confirmed IMN metastases, studies have proven a definite improvement of clinical outcomes if irradiation to the internal mammary nodal chain was performed [31, 32]. Veronesi et al. has observed patients with positive but receiving IMNs radiotherapy would experience a considerable excellent survival compared with the patients with negative IMN [33]. However, it also raises the risk of radiation-induced complications especially for pneumonitis and ischemic heart disease and inevitably challenge the complexity of the treatment planning due to its immediately adjacent to these organs. This suggests that it is of great importance to delineate the target fields appropriately so that it can reduce the relapse as well as spare the organs at risk. Thus a better knowledge of IMN anatomical structure would be indispensable for radiation oncologist.

In this study, we not only detail the anatomical and imaging characteristics of the IMN by analyzing distribution regularities of involved ribs, distance from the IMV to the nodal center, but also calculate the incidence differences in the of IMN involvement between left and right laterality. In particular, we try to figure out the natural extension of IMNs from IMV which would provide more information for the CTV delineation of visible IMN mass. Our results ultimately show that the location of the IMN metastasis was mostly observed in the first, second, and third intercostal spaces with few occurring caudal to the fourth rib and none in the fifth. Among those, the second intercostal space was the most likely involved in patients with single or multiple intercostal space involvement. This was consistent with other reports from extended radical mastectomy and autopsy studies, as well as from radiological images reviews that the vast majority of IMN recurrence were located within the first to third intercostal spaces [2, 6, 34]. Jethwa et al. also reported only 14% of lymph nodes were located in the fourth and fifth intercostal spaces among 130 invisible IMN metastases [35]. One study mentioned 100% IMN metastases occurred to the first to third intercostal spaces in the series of 61 patients who underwent extended radical mastectomy [10]. Nowadays, most of the current delineation guidelines for prophylactic IMN CTV limits the caudal border at the cranial edge of the fourth rib [21–24]. Our results, together with the aforementioned data have reaffirmed the rationality of the recommendations for prophylactic IMN delineation. But what is noteworthy is that in our study, four IMNs located at the forth intercostal space were extending from the upper one, indicating a rare prevalence of isolated IMN involvement in the fourth let alone fifth intercostal spaces in the absence of cranial IMN involvement in the IMN chain. That is to say, it would be reasonable to extend the caudal border in the cases with clinical IMN involvement in the first three intercostal spaces for prophylactic delineation.

Currently, most published guidelines, such as PROCAB, DBCG, and ESTRO guidelines, recommend a 5-mm medial and lateral expansion on the IM vessels to delineate the clinical target volume of internal mammary nodal chain, while RTOG guideline suggest the IMN target volume encompasses the IM vessels alone. Another study suggested that medial and lateral expansions as large as 6 mm would have encompassed 95% of IMNs for patients with known IMN involvement and those at very high risk of harboring microscopic disease via the analysis of 67 patients with IMN disease [35]. In our study, only 75.9% of lymph node could be encompassed with a 5-mm medial/lateral expansion on the IMV. Therefore, a 7 mm medial/lateral expansion to IMV might be appropriate to delineate the CTV of IMN, which covers 90% of IMNs, and a 6 mm expansion in the dorsal or ventral direction would be safe to include about 95% cases. The recommended medial and lateral expansion in the present study is larger than the current guidelines, one possible reason for this finding is the potential selection bias, because nearly 90% of the patients had larger IMN adenopathy in our series. Nevertheless, our finding is in accordance with the guideline enforced in our center with satisfied dose controlling to the heart and lungs.

Unlike anatomical features mentioned above, very few studies have focused on the natural extension of the internal mammary lymph nodes. It is generally acknowledged that tumors would always tend to grow in the direction with less resistance to acquire a fully extension. Interestingly, we found that 65.3% of the lesions expanded inwardly, that is, towards sternum side, which is different from the assumption that creeping along pleura towards the pulmonary lobe would provide more space for tumor growth. At present, CTV is obtained from gross tumor volume for visible IMN metastases especially among patients with subsequent IMN relapse. It is conceivable that areas at risk of harboring microscopic disease may not be fully congruent with areas harboring macroscopic disease. Given the situation that there is no specific consensus regarding the microscopic disease of metastatic IMN, the optimal CTV boundary has not been developed. From this point of view, our data has an obvious clinical significance suggesting that a deliberately appropriate expansion of CTV towards the sternum side would achieve a better disease control for
those with clinical IMN adenopathy. Consistent with our study, a recent report also mentioned IMN abutting the sternum and suggested to extend CTV coverage all the way to the sternal border [34, 36]. Interestingly, we observed a majority of IMNs (47/76, 61.8%) was located on the left and had more chance to get larger volume. A recent report from Japan has obtained the similar result [36]. Another latent proof is DBCG-IMN trial from which an obvious overall survival benefit but equal cardiac events have been acquired for patients with IMN irradiation on the right side compared with those without IMN irradiation on the left. However, further study with larger sample size and fundamental or translational researches are still needed to validate and confirm our findings.

Additionally, imaging plays a pivotal role in the management of cancer patients, including diagnosis, initial staging and treatment response assessment. MRI is the most efficient method, it is often used for initial diagnosis. While CT may be the most widely used tool throughout the treatment process, especially in patients with recurrence and metastasis, thus it is critical to improve the diagnostic accuracy. However, CT is prone to have missed diagnosis in cases with sternal metastases or chest wall recurrence. At the same time, as a non-invasive method, ultrasound plays an important role in detecting positive nodes to improve the diagnosis rate. When all inspection methods are used in combination, the diagnostic efficiency of IMN can be increased to 67.4%. Therefore, multimodal imaging was recommended to early detect abnormal IMN.

Several limitations are needed to be concerned in our study. First of all, positive IMNs were determined based on radiologic criteria and only 16.9% (14 of 83) of our patients had biopsy confirmation of their IMN metastasis. Secondly, our study is a retrospective study, thus the inherent selection bias could not be excluded. Finally, the sample size of the study is relatively small.

**Conclusions**

In conclusion, we mapped the location of IMN metastases to assist in optimizing the IMN CTV for volume-based breast cancer treating planning. In most of the patients indicated for IMN irradiation in the adjuvant setting, clinical target volume of IMN could be delineated with a 7 mm medial and 6 mm dorsal distance to the IMV on the same axial CT image which is in accordance with the recommendation in our center. In patients with evident metastatic IMNs, deliberate delineation towards sternum might be reasonable in terms with the natural extension orientation of IMN. This optimization in delineation might facilitate the balance of target coverage and normal tissue constraints. Multi-imaging mode recommended to improve the diagnostic specificity and sensitivity of IMN metastases.

**Abbreviations**

ALN: Axillary lymph nodes; CTV: Clinical tumor volume; FNA: Fine-needle aspiration; IMN: Internal mammary lymph nodes; IMRT: Intensity-modulate radiotherapy; IMV: Internal mammary vessel; RNI: Regional node irradiation

**Acknowledgements**

The piece has not been previously published and is not under consideration elsewhere. The persons listed as authors have given their approval for the submission.

**Authors’ contributions**

YJW collected and analysed the data, performed the statistical analysis and wrote the manuscript. MZ and CX helped with reviewing imaging slices. CX helped in drafting the manuscript. WXQ, HPX and JYC edited and critically revised the manuscript for valuable intellectual content. All authors read and gave their stamp of approval for the submission of the final version of the manuscript.

**Funding**

This study was supported in part by the National Natural Science Foundation of China (grant 81702601, grant 81673102, grant 81602791, grant 81803164).

**Availability of data and materials**

The datasets supporting the conclusions of this article are included within the article.

**Ethics approval and consent to participate**

All patients gave express written informed consent. Institutional Review Board approval was not required.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Department of Radiation Oncology, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, 197# Ruijin Er Road, Shanghai, China. 2 Department of Nuclear Medicine, Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, 197# Ruijin Er Road, Building 7, 3rd floor, Shanghai, China.

**Received:** 19 September 2019  **Accepted:** 30 October 2019  **Published online:** 21 November 2019

**References**

1. Handley RS, Thackray AC. Invasion of internal mammary lymph nodes in carcinoma of the breast. Br Med J. 1954;1(4853):61–3.
2. van der Ent FW, Kenenga RA, van der Pol HA, Povel JA, Stroeken HJ, Hoofwijk AG. Halsted revisited: internal mammary sentinel lymph node biopsy in breast cancer. Ann Surg. 2001;234(1):79–84.
3. Byrd DR, Dunning WD, Manhoff DA, Anderson BA, Moe RE, Yeung RS, et al. Internal mammary lymph node drainage patterns in patients with breast cancer documented by breast lymphoscintigraphy. Ann Surg Oncol. 2001;8(3):234–40.
4. Uren RF, Howman-Giles RB, Thompson JF, Malouf D, Ramsey-Stewart G, Niesche FW, et al. Mammary lymphoscintigraphy in breast cancer. J Nucl Med. 1995;36(10):1775–80.
5. Estourgie SH, Newey OE, Olmos RA, Rutgers EJ, Kooon BB. Lymphatic drainage patterns from the breast. Ann Surg. 2004;239(2):232–7.
6. Huang O, Wang L, Shen K, Lin H, Hu Z, Liu G, et al. Breast cancer subpopulation with high risk of internal mammary lymph nodes metastasis: analysis of 2,269 Chinese breast cancer patients treated with extended radical mastectomy. Breast Cancer Res Treat. 2008;107(3):379–87.
7. Veronesi U, Cacicini N, Bufalino R, Morabito A, Greco M, Galluzzo D, et al. Risk of internal mammary lymph node metastasis and its relevance on prognosis of breast cancer patients. Ann Surg. 1983;198(6):681–4.
8. Cody HS 3rd, Urban JA. Internal mammary node status: a major prognosticator in axillary node-negative breast cancer. Ann Surg Oncol. 1995;2(1):32–7.

9. Donegan WL. The influence of untreated internal mammary metastases upon the course of mammary cancer. Cancer. 1977;39(2):533–8.

10. DeSelm C, Yang TJ, Cahlon O, Tisnado J, Khan A, Gillespie E, et al. A 3-dimensional mapping analysis of regional nodal recurrences in breast cancer. Int J Radiat Oncol Biol Phys. 2019;103(3):583–91.

11. Cranenbroek S, van der Sangen MJ, Kuitj GP, Voogd AC. Diagnosis, treatment and prognosis of internal mammary lymph node recurrence in breast cancer patients. Breast Cancer Res Treat. 2005;89(3):271–5.

12. Arrigada R, Le MG, Moulines H, Fontaine F, Dewar J, Rochard F, et al. Long-term effect of internal mammary chain treatment: Results of a multivariate analysis of 1195 patients with operable breast cancer and positive axillary nodes. Radiother Oncol. 1998;46(1):213–22.

13. Poortmans P, Collette S, Strulckmans H, Winter KD, Limbergen EV, Kirkove C, et al. Fifteen-year results of the randomised EORTC trial 22922/10925 investigating internal mammary and medial supraclavicular (IM-SM) lymph node irradiation in stage I-II breast cancer. J Clin Oncol. 2019;37(15_suppl):504.

14. McGale P, Taylor C, Correa C, Cutter D, Duane F, Ewertz M, et al. Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8173 women in 22 randomised trials. Lancet (London, England). 2014; 383(9933):2127–35.

15. Whelan TJ, Olivotto JA, Parulekar WR, Ackerman I, Chua BH, Nabid A, et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med. 2015; 373(4):307–16.

16. Thorsen LB, Offersen BV, Dano H, Berg M, Jensen I, Pedersen AN, et al. Delineation of target volumes and organs at risk in adjuvant radiation therapy. J Clin Oncol. 2013;31(32):4038–45.

17. Darby SC, Ewertz M, McGale P, Bennett AM, Blom-Goldman U, Bronnum D, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med. 2013;368(11):987–98.

18. Taylor C, Correa C, Duane FK, Aznar MC, Anderson SJ, Bergh J, et al. Estimating the risks of breast cancer radiotherapy: evidence from modern radiation doses to the lungs and heart and from previous randomized trials. J Clin Oncol. 2017;35(15):1641–9.

19. Cao L, Cai G, Chang C, Miao AY, Yu XL, Yang ZZ, et al. Diastolic dysfunction occurs early in HER2-positive breast Cancer patients treated concurrently with radiation therapy and Trastuzumab. Oncologist. 2015;20(6):605–14.

20. Cao L, Hu WG, Kirova YM, Yang ZZ, Cai G, Yu XL, et al. Potential impact of cardiac dose-volume on acute cardiac toxicity following concurrent trastuzumab and radiotherapy. Cancer Radiother. 2014;18(2):119–24.

21. de Graaf H, Dolmsa WW, Willemsen PH, van der Graaf WT, Steijger DT, de Vries EG, et al. Cardiotoxicity from intensive chemotherapy combined with radiotherapy in breast cancer. Br J Cancer. 1997;76(7):943–5.

22. Hardenbergh PH, Munley MT, Bentel GC, Kedem R, Borjes-Neto S, Hollis D, et al. Cardiac perfusion changes in patients treated for breast cancer with radiation therapy and doxorubicin: preliminary results. Int J Radiat Oncol Biol Phys. 2001;49(4):1023–8.

23. Verhoeven K, Welten C, Romboucharps V, Mahjoubi K, Velderman L, Lengele B, et al. Vessel based delineation guidelines for the elective lymph node regions in breast cancer radiation therapy - PROCAB guidelines. Radio Oncol. 2016;11(1):209–10.

24. Offersen BV, Boersma LJ, Kirkove C, Hol S, Aznar MC, Sola AB, et al. ESTRO consensus guideline on target volume delineation for elective radiation therapy of early stage breast cancer, version 1.1. Radiother Oncol. 2016; 118(1):205–8.

25. Olivotto IA, Whelan TJ, Parpia S, Kim DH, Berrang T, Truong PT, et al. Interim cosmetic and toxicity results from RAPID: a randomized trial of accelerated partial breast irradiation using three-dimensional conformal external beam radiation therapy. J Clin Oncol. 2013;31(32):4038–45.

26. Nielsen MH, Berg M, Pedersen AN, Andersen K, Glavicz V, Jakobsen EH, et al. Delineation of target volumes and organs at risk in adjuvant radiotherapy of early breast cancer: national guidelines and contouring atlas by the Danish Breast Cancer Cooperative Group. Acta Oncologica (Stockholm, Sweden). 2013;52(4):703–10.

27. Cheon H, Kim HJ, Lee SW, Kim DH, Lee CH, Cho SH, et al. Internal mammary node adenopathy on breast MRI and PET/CT for initial staging in patients with operable breast cancer: prevalence and associated factors. Breast Cancer Res Treat. 2016;160(3):523–30.

28. Noushi F, Spillane AJ, Uren RF, Gelski V. Internal mammary lymph node metastasis in breast cancer: predictive models to assist with prognostic influence. Breast (Edinburgh, Scotland). 2011;20(3):278–83.

29. Kinoshita T, Odagiri K, Andoh K, Doiuchi T, Sugimura K, Shiotani S, et al. Evaluation of small internal mammary lymph node metastases in breast cancer by MRI. Radiat Med. 1999;17(3):189–93.

30. Savardias SL, Spratt JD, Cox J. Incidence and potential significance of internal mammary lymphadenopathy on computed tomography in patients with a diagnosis of primary breast Cancer. Breast Cancer (Auckl). 2015;5:559–65.

31. Zhang YJ, Oh JL, Whitman GJ, Jyengar P, Yu TK, Tereffie W, et al. Clinically apparent internal mammary nodal metastasis in patients with advanced breast cancer: incidence and local control. Int J Radiat Oncol Biol Phys. 2010;77(4):1113–9.

32. Heuts EM, van der Ent FW, Hulssewe KW, von Meyenfeldt MF, Voogd AC. Results of tailored treatment for breast cancer patients with internal mammary lymph node metastases. Breast (Edinburgh, Scotland). 2009; 18(4):254–8.

33. Veronesi U, Arnone P, Veronesi P, Galimberti V, Luini A, Rotmensz N, et al. The value of radiotherapy on metastatic internal mammary nodes in breast cancer. Results on a large series. Ann Oncol. 2008;19(9):1553–60.

34. Yu JL, Li G, Li J, Wang Y. The pattern of lymphatic metastasis of breast cancer and its influence on the delineation of radiation fields. Int J Radiat Oncol Biol Phys. 2005;61(3):874–8.

35. Jethwa KR, Kahila MM, Hunt KN, Brown LC, Corbin KS, Park SS, et al. Delineation of internal mammary nodal target volumes in breast Cancer radiotherapy. Int J Radiat Oncol Biol Phys. 2017;94(6):762–9.

36. Urano M, Denewar FA, Murai T, Mitani M, Kitase M, Ohashi K, et al. Internal mammary lymph node metastases in breast cancer: what should radiologists know? Jpn J Radiol. 2018;36(11):629–40.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.